Actavis won the FDA's approval on 25 February to market Avycaz, an antibiotic combination containing ceftazidime and avibactam, to treat complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
The drug is intended for use in adults who have limited or no alternative treatment options to treat those diseases.





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
